Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The objective of this study is to explore the effects of Sirolimus on the underlying
molecular alterations of cerebral aneurysms.
Phase
Phase 2
Funding Agency/Sponsor
Other
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
1. Undergoing one of the following procedures at Jackson Memorial Hospital:
- Clipping of an unruptured cerebral artery aneurysm
- Endovascular treatment of unruptured cerebral aneurysms (including those
receiving coiling)
2. ≥ 18 years of age
3. Willing and able to give informed consent
Exclusion Criteria:
1) Subjects meeting any of the following criteria will be excluded:
- Dissecting, traumatic, or mycotic brain aneurysm.
- Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
- Women who are breastfeeding.
- Any clinically significant psychiatric or psychological disease, which would preclude
the patient from completing the protocol.
- Patients with known Human Immunodeficiency Virus (HIV) infection or other known
immunodeficiency.
- Patient with renal or liver failure
- Interstitial pneumonitis
- History of lymphoma
- History of skin cancer
- Hypersensitivity to sirolimus
- Severe or unstable concomitant condition disease or chronic condition, which in the
opinion of the investigator could affect assessment of the safety or efficacy of study
intervention.